News

Genesis Energy (NYSE:GEL) said first-quarter 2026 results came in “a touch below” its internal expectations, primarily due to anticipated offshore producer turnarounds, lower-than-expected

• A New Leader at Six Flags: Is the Roller Coaster Over?

Six Flags Entertainment (NYSE:FUN) reported improved first-quarter 2026 operating trends, with management pointing to higher attendance

• Bullish or Bearish? Vetting Animal Health Care Stocks

Elanco Animal Health (NYSE:ELAN) raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based

• 3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill

CVS Health (NYSE:CVS) raised its full-year 2026 adjusted earnings outlook after reporting stronger first-quarter results, with

CareTrust REIT (NYSE:CTRE) reported a strong start to 2026, highlighting rapid investment activity, higher funds from operations and an increased full-year outlook during its first-quarter earnings

Accel Entertainment (NYSE:ACEL) held its 2026 Annual Meeting of Stockholders, with shareholders voting to elect directors, approve executive compensation on an advisory basis and ratify the

• 3 Beaten Up Experiential Stocks to Cash in on a Good Time

Bowlero (NYSE:BOWL), referred to by executives on the call as Lucky Strike Entertainment, reported a modest increase in fiscal

• 3 Satellite Stocks To Check Out Before SpaceX's IPO

BlackSky Technology (NYSE:BKSY) raised its 2026 revenue and adjusted EBITDA outlook after reporting first-quarter results that management said

• The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company

• Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal

Artivion (NYSE:AORT) executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due

• Zai Lab Stock Has Fallen to Value Levels

Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management

Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent

• Tax Software Specialist Vertex In Buy Zone After Base Breakout

Vertex (NASDAQ:VERX) reported first-quarter 2026 results above its guidance range and raised its full-year profitability outlook as

• 5 medical stocks growing earnings by triple digits

Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage

Oncology Institute (NASDAQ:TOI) reported a strong start to 2026, with first-quarter revenue rising 41% year over year as the company expanded value-based care arrangements and posted record

Tandem Diabetes Care (NASDAQ:TNDM) reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift

• 3 Value Stocks Flying Under the Radar—For Now

E.W. Scripps (NASDAQ:SSP) reported first-quarter 2026 results that management said reflected progress on a broad transformation plan, stronger local

• Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment

Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in

PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria

Privia Health Group (NASDAQ:PRVA) reported a strong first quarter, with executives pointing to double-digit provider growth, a larger value-based care population and margin expansion as signs that

Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use

Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026

Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting

• Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?

Palomar (NASDAQ:PLMR) reported a strong start to 2026, with management highlighting broad-based premium growth, continued